Aktienkurs

Dato	Tianjin Pharmaceutical Da Ren Tang Group Corp Omsætning	Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT	Tianjin Pharmaceutical Da Ren Tang Group Corp Indtjening
2026e	10,96 mia. undefined	1,65 mia. undefined	1,73 mia. undefined
2025e	10,00 mia. undefined	1,34 mia. undefined	1,46 mia. undefined
2024e	9,12 mia. undefined	1,08 mia. undefined	1,21 mia. undefined
2023	8,22 mia. undefined	814,79 mio. undefined	986,71 mio. undefined
2022	8,25 mia. undefined	681,08 mio. undefined	861,79 mio. undefined
2021	6,91 mia. undefined	592,64 mio. undefined	769,14 mio. undefined
2020	6,60 mia. undefined	587,50 mio. undefined	661,70 mio. undefined
2019	6,99 mia. undefined	536,80 mio. undefined	625,60 mio. undefined
2018	6,36 mia. undefined	468,00 mio. undefined	561,70 mio. undefined
2017	5,69 mia. undefined	348,30 mio. undefined	476,10 mio. undefined
2016	6,24 mia. undefined	295,80 mio. undefined	423,60 mio. undefined
2015	7,08 mia. undefined	393,20 mio. undefined	451,40 mio. undefined
2014	7,09 mia. undefined	372,50 mio. undefined	357,80 mio. undefined
2013	6,01 mia. undefined	344,10 mio. undefined	351,80 mio. undefined
2012	5,13 mia. undefined	268,00 mio. undefined	441,30 mio. undefined
2011	4,39 mia. undefined	271,90 mio. undefined	247,60 mio. undefined
2010	3,47 mia. undefined	236,80 mio. undefined	293,30 mio. undefined
2009	2,88 mia. undefined	168,40 mio. undefined	257,80 mio. undefined
2008	2,37 mia. undefined	92,50 mio. undefined	176,10 mio. undefined
2007	2,26 mia. undefined	-185,70 mio. undefined	-70,00 mio. undefined
2006	2,16 mia. undefined	-408,20 mio. undefined	-386,60 mio. undefined
2005	2,52 mia. undefined	51,30 mio. undefined	80,80 mio. undefined
2004	2,12 mia. undefined	73,10 mio. undefined	64,00 mio. undefined

	Omsætning	EBIT	Indtjening
2004	2,12 mia. CNY	73,10 mio. CNY	64,00 mio. CNY
2005	2,52 mia. CNY	51,30 mio. CNY	80,80 mio. CNY
2006	2,16 mia. CNY	-408,20 mio. CNY	-386,60 mio. CNY
2007	2,26 mia. CNY	-185,70 mio. CNY	-70,00 mio. CNY
2008	2,37 mia. CNY	92,50 mio. CNY	176,10 mio. CNY
2009	2,88 mia. CNY	168,40 mio. CNY	257,80 mio. CNY
2010	3,47 mia. CNY	236,80 mio. CNY	293,30 mio. CNY
2011	4,39 mia. CNY	271,90 mio. CNY	247,60 mio. CNY
2012	5,13 mia. CNY	268,00 mio. CNY	441,30 mio. CNY
2013	6,01 mia. CNY	344,10 mio. CNY	351,80 mio. CNY
2014	7,09 mia. CNY	372,50 mio. CNY	357,80 mio. CNY
2015	7,08 mia. CNY	393,20 mio. CNY	451,40 mio. CNY
2016	6,24 mia. CNY	295,80 mio. CNY	423,60 mio. CNY
2017	5,69 mia. CNY	348,30 mio. CNY	476,10 mio. CNY
2018	6,36 mia. CNY	468,00 mio. CNY	561,70 mio. CNY
2019	6,99 mia. CNY	536,80 mio. CNY	625,60 mio. CNY
2020	6,60 mia. CNY	587,50 mio. CNY	661,70 mio. CNY
2021	6,91 mia. CNY	592,64 mio. CNY	769,14 mio. CNY
2022	8,25 mia. CNY	681,08 mio. CNY	861,79 mio. CNY
2023	8,22 mia. CNY	814,79 mio. CNY	986,71 mio. CNY
2024e	9,12 mia. CNY	1,08 mia. CNY	1,21 mia. CNY
2025e	10,00 mia. CNY	1,34 mia. CNY	1,46 mia. CNY
2026e	10,96 mia. CNY	1,65 mia. CNY	1,73 mia. CNY

Tianjin Pharmaceutical Da Ren Tang Group Corp Bruttomargin	Tianjin Pharmaceutical Da Ren Tang Group Corp Overskudsmargen	Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT-margin	Tianjin Pharmaceutical Da Ren Tang Group Corp Overskudsmargen
2026e	43,66 %	15,09 %	15,80 %
2025e	43,66 %	13,36 %	14,58 %
2024e	43,66 %	11,84 %	13,24 %
2023	43,66 %	9,91 %	12,00 %
2022	39,49 %	8,26 %	10,45 %
2021	39,76 %	8,58 %	11,13 %
2020	39,07 %	8,90 %	10,02 %
2019	41,76 %	7,68 %	8,94 %
2018	41,20 %	7,36 %	8,83 %
2017	38,68 %	6,12 %	8,37 %
2016	32,27 %	4,74 %	6,79 %
2015	29,48 %	5,55 %	6,38 %
2014	30,27 %	5,26 %	5,05 %
2013	31,86 %	5,73 %	5,85 %
2012	34,12 %	5,22 %	8,60 %
2011	34,85 %	6,19 %	5,64 %
2010	37,77 %	6,82 %	8,44 %
2009	37,54 %	5,85 %	8,95 %
2008	36,93 %	3,91 %	7,45 %
2007	34,28 %	-8,22 %	-3,10 %
2006	35,01 %	-18,86 %	-17,86 %
2005	42,58 %	2,04 %	3,21 %
2004	45,13 %	3,45 %	3,02 %

	Bruttomargin	EBIT-margin	Overskudsmargen
2004	45,13 %	3,45 %	3,02 %
2005	42,58 %	2,04 %	3,21 %
2006	35,01 %	-18,86 %	-17,86 %
2007	34,28 %	-8,22 %	-3,10 %
2008	36,93 %	3,91 %	7,45 %
2009	37,54 %	5,85 %	8,95 %
2010	37,77 %	6,82 %	8,44 %
2011	34,85 %	6,19 %	5,64 %
2012	34,12 %	5,22 %	8,60 %
2013	31,86 %	5,73 %	5,85 %
2014	30,27 %	5,26 %	5,05 %
2015	29,48 %	5,55 %	6,38 %
2016	32,27 %	4,74 %	6,79 %
2017	38,68 %	6,12 %	8,37 %
2018	41,20 %	7,36 %	8,83 %
2019	41,76 %	7,68 %	8,94 %
2020	39,07 %	8,90 %	10,02 %
2021	39,76 %	8,58 %	11,13 %
2022	39,49 %	8,26 %	10,45 %
2023	43,66 %	9,91 %	12,00 %
2024e	43,66 %	11,84 %	13,24 %
2025e	43,66 %	13,36 %	14,58 %
2026e	43,66 %	15,09 %	15,80 %

Dato	Tianjin Pharmaceutical Da Ren Tang Group Corp Omsætning per aktie	Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT per aktie	Tianjin Pharmaceutical Da Ren Tang Group Corp Indtjening per aktie
2026e	14,25 undefined	0 undefined	2,25 undefined
2025e	13,01 undefined	0 undefined	1,90 undefined
2024e	11,86 undefined	0 undefined	1,57 undefined
2023	10,69 undefined	1,06 undefined	1,28 undefined
2022	10,63 undefined	0,88 undefined	1,11 undefined
2021	8,98 undefined	0,77 undefined	1,00 undefined
2020	8,59 undefined	0,76 undefined	0,86 undefined
2019	9,10 undefined	0,70 undefined	0,81 undefined
2018	8,26 undefined	0,61 undefined	0,73 undefined
2017	7,40 undefined	0,45 undefined	0,62 undefined
2016	8,12 undefined	0,38 undefined	0,55 undefined
2015	9,21 undefined	0,51 undefined	0,59 undefined
2014	9,59 undefined	0,50 undefined	0,48 undefined
2013	8,13 undefined	0,47 undefined	0,48 undefined
2012	6,94 undefined	0,36 undefined	0,60 undefined
2011	5,94 undefined	0,37 undefined	0,33 undefined
2010	4,70 undefined	0,32 undefined	0,40 undefined
2009	3,90 undefined	0,23 undefined	0,35 undefined
2008	3,20 undefined	0,13 undefined	0,24 undefined
2007	3,05 undefined	-0,25 undefined	-0,09 undefined
2006	2,93 undefined	-0,55 undefined	-0,52 undefined
2005	3,40 undefined	0,07 undefined	0,11 undefined
2004	2,86 undefined	0,10 undefined	0,09 undefined

	Omsætning per aktie	EBIT per aktie	Indtjening per aktie
2004	2,86 CNY	0,10 CNY	0,09 CNY
2005	3,40 CNY	0,07 CNY	0,11 CNY
2006	2,93 CNY	-0,55 CNY	-0,52 CNY
2007	3,05 CNY	-0,25 CNY	-0,09 CNY
2008	3,20 CNY	0,13 CNY	0,24 CNY
2009	3,90 CNY	0,23 CNY	0,35 CNY
2010	4,70 CNY	0,32 CNY	0,40 CNY
2011	5,94 CNY	0,37 CNY	0,33 CNY
2012	6,94 CNY	0,36 CNY	0,60 CNY
2013	8,13 CNY	0,47 CNY	0,48 CNY
2014	9,59 CNY	0,50 CNY	0,48 CNY
2015	9,21 CNY	0,51 CNY	0,59 CNY
2016	8,12 CNY	0,38 CNY	0,55 CNY
2017	7,40 CNY	0,45 CNY	0,62 CNY
2018	8,26 CNY	0,61 CNY	0,73 CNY
2019	9,10 CNY	0,70 CNY	0,81 CNY
2020	8,59 CNY	0,76 CNY	0,86 CNY
2021	8,98 CNY	0,77 CNY	1,00 CNY
2022	10,63 CNY	0,88 CNY	1,11 CNY
2023	10,69 CNY	1,06 CNY	1,28 CNY
2024e	11,86 CNY	0 CNY	1,57 CNY
2025e	13,01 CNY	0 CNY	1,90 CNY
2026e	14,25 CNY	0 CNY	2,25 CNY

	Antal aktier
2004	739,30 mio. Aktien
2005	739,30 mio. Aktien
2006	739,30 mio. Aktien
2007	739,30 mio. Aktien
2008	739,30 mio. Aktien
2009	739,30 mio. Aktien
2010	739,30 mio. Aktien
2011	739,30 mio. Aktien
2012	739,30 mio. Aktien
2013	739,30 mio. Aktien
2014	739,30 mio. Aktien
2015	768,90 mio. Aktien
2016	768,90 mio. Aktien
2017	768,90 mio. Aktien
2018	769,40 mio. Aktien
2019	768,90 mio. Aktien
2020	768,90 mio. Aktien
2021	769,14 mio. Aktien
2022	776,39 mio. Aktien
2023	768,87 mio. Aktien
2024e	768,87 mio. Aktien
2025e	768,87 mio. Aktien
2026e	768,87 mio. Aktien

Dato	Tianjin Pharmaceutical Da Ren Tang Group Corp Udbytte
2026e	1,21 undefined
2025e	1,21 undefined
2024e	1,21 undefined
2023	1,12 undefined
2022	0,50 undefined
2021	0,30 undefined
2020	0,30 undefined
2019	0,22 undefined
2018	0,20 undefined
2017	0,15 undefined
2016	0,25 undefined
2015	0,15 undefined
2014	0,05 undefined
2013	0,10 undefined
2012	0,20 undefined
2011	0,20 undefined
2006	0,08 undefined
2005	0,08 undefined
2004	0,08 undefined

	Udbytte	Udbytte (estimat)
2004	0,08 CNY	0 CNY
2005	0,08 CNY	0 CNY
2006	0,08 CNY	0 CNY
2007	0 CNY	0 CNY
2008	0 CNY	0 CNY
2009	0 CNY	0 CNY
2010	0 CNY	0 CNY
2011	0,20 CNY	0 CNY
2012	0,20 CNY	0 CNY
2013	0,10 CNY	0 CNY
2014	0,05 CNY	0 CNY
2015	0,15 CNY	0 CNY
2016	0,25 CNY	0 CNY
2017	0,15 CNY	0 CNY
2018	0,20 CNY	0 CNY
2019	0,22 CNY	0 CNY
2020	0,30 CNY	0 CNY
2021	0,30 CNY	0 CNY
2022	0,50 CNY	0 CNY
2023	1,12 CNY	0 CNY
2024e	0 CNY	1,21 CNY
2025e	0 CNY	1,21 CNY
2026e	0 CNY	1,21 CNY

Dato	Tianjin Pharmaceutical Da Ren Tang Group Corp Udbetalingsrate
2026e	37,84 %
2025e	39,64 %
2024e	37,23 %
2023	36,64 %
2022	45,05 %
2021	30,00 %
2020	34,88 %
2019	27,16 %
2018	27,40 %
2017	24,19 %
2016	45,45 %
2015	25,42 %
2014	10,42 %
2013	20,83 %
2012	33,33 %
2011	60,61 %
2010	36,64 %
2009	36,64 %
2008	36,64 %
2007	36,64 %
2006	-14,42 %
2005	68,18 %
2004	83,33 %

	Udbetalingsrate
2004	83,33 %
2005	68,18 %
2006	-14,42 %
2007	36,64 %
2008	36,64 %
2009	36,64 %
2010	36,64 %
2011	60,61 %
2012	33,33 %
2013	20,83 %
2014	10,42 %
2015	25,42 %
2016	45,45 %
2017	24,19 %
2018	27,40 %
2019	27,16 %
2020	34,88 %
2021	30,00 %
2022	45,05 %
2023	36,64 %
2024e	37,23 %
2025e	39,64 %
2026e	37,84 %

Dato	EPS-estimat	EPS-Actual	Regnskabskvartal
31.12.2014	0,22	0,13 (-41,49 %)	2014 Q4
30.9.2014	0,18	0,08 (-56,00 %)	2014 Q3
30.6.2014	0,15	0,13 (-14,19 %)	2014 Q2
31.12.2013	0,21	0,16 (-24,56 %)	2013 Q4
30.9.2013	0,14	0,06 (-57,57 %)	2013 Q3
30.6.2013	0,13	0,10 (-20,82 %)	2013 Q2

%	Navn	Aktier	Ændring	Dato
42,38 %	Tianjin Pharmaceutical Holdings Ltd.	325.855.528	0	31.12.2023
1,09 %	Fullgoal Fund Management Co., Ltd.	8.392.119	-340.800	31.12.2023
0,70 %	Zhong Ou Asset Management Co., Ltd.	5.348.982	-8.489.300	31.12.2023
0,61 %	GF Fund Management Co., Ltd.	4.711.501	-1.989.900	31.12.2023
0,57 %	Chen (Shihui)	4.418.118	4.418.118	31.12.2023
0,54 %	China Universal Asset Management Co., Ltd.	4.124.015	-422.094	31.12.2023
0,31 %	Hotland Innovation Asset Management Co., Ltd.	2.413.803	-230.080	31.12.2023
0,29 %	E Fund Management Co. Ltd.	2.252.050	-2.748.720	30.6.2023
0,29 %	China Southern Asset Management Co. Ltd.	2.228.492	117.800	31.12.2023
0,27 %	ICBC Credit Suisse Asset Management Co. Ltd.	2.107.589	-243.100	31.12.2023
0,23 %	Cinda Fund Management Co., Ltd.	1.805.256	-2.020.600	31.12.2023
0,22 %	China Asset Management Co., Ltd.	1.722.109	53.900	31.12.2023
0,21 %	Bosera Asset Management Co., Ltd.	1.589.300	-30.200	31.12.2023
0,20 %	Penghua Fund Management Co., Ltd.	1.510.738	310.800	30.6.2023
0,19 %	ZhongRong Fund Mgmt Co., Ltd	1.434.538	-638.862	30.6.2023
0,17 %	The Vanguard Group, Inc.	1.311.297	0	31.3.2024
0,16 %	JPMorgan Asset Management (China) Company Limited.	1.254.249	1.214.649	30.6.2023
0,15 %	China Merchants Fund Management Co. Ltd.	1.153.883	-160.300	31.12.2023
0,14 %	Western Leadbank Fund Management Co., Ltd.	1.040.100	1.040.100	30.6.2023
0,12 %	CCB Principal Asset Management Co., Ltd.	913.135	103.700	31.12.2023
0,11 %	AXA-SPDB Investment Managers Co., Ltd.	813.400	695.400	31.12.2023
0,10 %	Harvest Fund Management Co., Ltd.	803.209	-741.615	30.6.2023
0,09 %	Guotai Junan Securities Assets Management Co., Ltd.	692.400	692.400	30.6.2023
0,09 %	Broad Asset Management Co., Ltd	686.600	686.600	30.6.2023
0,08 %	Great Wall Fund Management Co., Ltd.	628.300	-21.700	31.12.2023
0,08 %	Tianhong Asset Management Co., Ltd.	579.300	14.300	31.12.2023
0,07 %	CITIC Prudential Fund Management Co., Ltd.	560.672	500.000	31.12.2023
0,07 %	Zhong Hai Fund Management Co., Ltd.	548.127	548.127	31.12.2023
0,06 %	Changsheng Fund Management Co., Ltd.	498.100	-25.400	31.12.2023
0,06 %	Morgan Stanley Investment Management (China) Company Limited.	480.200	30.300	30.6.2023
0,06 %	Founder Fubon Fund Management Co., Ltd.	460.677	0	31.12.2023
0,06 %	Norges Bank Investment Management (NBIM)	458.108	458.108	31.12.2023
0,05 %	First-Trust Fund Management Co., Ltd.	388.188	-157.228	30.6.2023
0,05 %	Hongde Fund Management Co., Ltd.	349.200	-696.900	30.6.2023
0,04 %	Bank of Communications Schroder Fund Management Co., Ltd.	297.773	-5.088.456	30.6.2023
0,04 %	Baoying Fund Management Co., Ltd.	273.100	-499.300	31.12.2023
0,03 %	Dacheng Fund Management Co., Ltd.	260.201	256.600	30.6.2023
0,03 %	Value Partners Ltd.	246.572	-41.400	31.12.2023
0,03 %	Maxwealth Fund Management Co., Ltd.	220.000	218.100	30.6.2023
0,03 %	Chang Xin Asset Management Co., Ltd.	212.000	-269.200	31.12.2023
0,03 %	PengYang Asset Management Co., Ltd	207.000	207.000	30.6.2023
0,03 %	Huashang Fund Management Co., Ltd.	200.000	200.000	30.6.2023
0,03 %	Dimensional Fund Advisors, L.P.	198.372	-200	29.2.2024
0,03 %	Yinhua Fund Management Co., Ltd.	198.031	125.400	31.12.2023
0,03 %	Everbright PGIM Fund Management Co., Ltd.	197.000	-179.100	30.6.2023
0,02 %	CICC Fund Management Co Ltd.	170.700	-6.500	31.12.2023
0,02 %	INVESCO Great Wall Fund Management Co. Ltd.	167.255	-3.200	31.12.2023
0,02 %	Wanjia Asset Management Co., Ltd.	167.159	-2.781.983	30.6.2023
0,02 %	BOC International (China) Ltd.	142.800	200	31.12.2023
0,02 %	Hwabao WP Fund Management Co., Ltd.	116.000	90.000	31.12.2023
0,01 %	Huatai-PineBridge Fund Management Co., Ltd.	112.780	-214.603	30.6.2023
0,01 %	TongTai Asset Management Co., Ltd.	103.700	103.700	30.6.2023
0,01 %	Focusbridge Investments Limited	98.000	98.000	30.6.2023
0,01 %	Orient Securities Asset Management Company Limited	95.600	95.600	30.6.2023
0,01 %	Handelsbanken Kapitalförvaltning AB	95.500	0	31.3.2024
0,01 %	UBS SDIC Fund Management Co., Ltd.	92.800	15.100	31.12.2023
0,01 %	BOSC Asset Management Co., Ltd.	87.700	-33.600	31.12.2023
0,01 %	Ping An Fund Management Company Limited	77.400	-6.200	31.12.2023
0,01 %	ABC-CA Fund Management Co., Ltd.	68.100	-2.897.300	31.12.2023
0,01 %	Xinghua Fund Management Co., Ltd.	48.200	48.200	30.6.2023
0,01 %	Soochow Asset Management Co., Ltd.	47.200	-34.900	31.12.2023
0,01 %	China Fund Management Co., Ltd.	41.600	-28.600	31.12.2023
0,01 %	Guotai Asset Management Co., Ltd.	38.700	-445.509	30.6.2023
0,00 %	BlackRock Investment Management (UK) Ltd.	38.200	0	29.2.2024
0,00 %	SWS MU Fund Management Co., Ltd.	33.300	33.300	30.6.2023
0,00 %	JX Asset Management Co., Ltd.	32.078	-84.800	30.6.2023
0,00 %	Topsperity Fund Management Co., Ltd.	31.900	22.300	31.12.2023
0,00 %	Taikang Asset Management Co., Ltd.	28.100	25.000	31.12.2023
0,00 %	CITIC Securities Co., Ltd. (Asset Management)	27.600	27.600	30.6.2023
0,00 %	Donghai Funds Management Co., Ltd.	26.800	26.800	30.6.2023
0,00 %	Manulife Fund Management Co., Ltd.	25.700	1.000	31.12.2023
0,00 %	Sealand Securities Co., Ltd.	23.849	14.349	30.6.2023
0,00 %	Zhou (Hong)	23.800	-46.200	31.12.2023
0,00 %	Wang (Xin)	23.800	-46.200	31.12.2023
0,00 %	Niu (Sheng Fang)	23.800	-46.200	31.12.2023
0,00 %	Horizon Asset Management Co., Ltd.	20.700	-4.100	30.6.2023
0,00 %	AVIC Fund Management Co., Ltd.	18.700	12.600	30.6.2023
0,00 %	Caitong Fund Management Co., Ltd.	18.100	-31.200	31.12.2023
0,00 %	China Life AMP Asset Management Co., Ltd	17.200	-300	31.12.2023
0,00 %	China Everbright Assets Management, Ltd.	17.000	17.000	30.6.2023
0,00 %	HuaAn Fund Management Co., Ltd.	16.900	-1.328.600	30.6.2023
0,00 %	Goldstate Capital Fund Management Co., Ltd.	15.000	15.000	30.6.2023
0,00 %	CPIC Fund Management Co., Ltd.	14.500	14.500	30.6.2023
0,00 %	DBX Advisors LLC.	13.900	13.900	29.2.2024
0,00 %	Nykredit Bank AS	13.400	0	29.2.2024
0,00 %	Dimensional Fund Advisors, Ltd.	13.000	-6.600	29.2.2024
0,00 %	Minsheng Royal Fund Management Company Ltd.	12.200	4.800	30.6.2023
0,00 %	Neuberger Berman Fund Management (China) Co., Ltd.	11.739	11.739	30.6.2023
0,00 %	Truvalue Asset Management Co., Ltd.	10.500	-1.186.838	30.6.2023
0,00 %	Jiao (Yan)	10.200	-19.800	31.12.2023
0,00 %	Shanghai Haitong Securities Asset Management Ltd.	10.100	-3.800	31.12.2023
0,00 %	Tibet Eastmoney Fund Management Co., Ltd.	9.500	-100	30.6.2023
0,00 %	Xingyin Fund Management Co., Ltd.	9.300	9.300	30.6.2023
0,00 %	Orient Fund Management Co. Ltd.	9.000	-70.000	30.6.2023
0,00 %	Harvest Global Investments Limited	7.162	0	29.2.2024
0,00 %	Jyah Asset Management.Co.,LTD	7.000	5.500	30.6.2023
0,00 %	Golden Trust Sinopac Fund Management Co., Ltd.	6.500	6.500	30.6.2023
0,00 %	Essence Fund Management Co., Ltd.	6.100	-9.400	31.12.2023
0,00 %	Everbright Securities Asset Management Co., Ltd.	5.800	-5.900	31.12.2023
0,00 %	Northeast Ronghui Securities Asset Management Co., Ltd.	4.900	4.900	30.6.2023

Navn	Forhold	To-ugers korrelation	Enmånedskorrelation	Trekvartalskorrelation	Seksmånederskorrelation	Étårig korrelation	To-års korrelation
Citigroup	LeverandørKunde	0,69	-0,04	0,80	0,66	0,43	0,57
GlaxoSmithKline	LeverandørKunde	0,36	-0,43	-0,80	-0,59	-0,42	0,31
Standard Chartered	LeverandørKunde	0,33	0,71	-0,68	-0,32	-0,34	0,26
Tianjin Lisheng Pharm A	LeverandørKunde	0,12	0,91	0,83	0,28	0,17	-0,40
Tianjin Development Hldgs	LeverandørKunde	0,05	-0,58	0,72	0,34	0,18	0,54
DBS Group Holdings	LeverandørKunde	-0,53	-0,72	0,53	0,47	0,02	0,75
ABN AMRO DR	LeverandørKunde	-0,70	-0,75	-0,21	0,60	0,30	0,78

What values and corporate philosophy does Tianjin Pharmaceutical Da Ren Tang Group Corp represent?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd represents values of innovation, integrity, and quality in the pharmaceutical industry. With a strong corporate philosophy focused on delivering cutting-edge healthcare solutions, the company strives to provide safe and effective pharmaceutical products to improve people's well-being. Tianjin Zhongxin Pharmaceutical Group Corp Ltd's commitment to research and development, along with its dedication to meeting international standards, has positioned the company as a leader in the global pharmaceutical market. Through its emphasis on quality control, continuous improvement, and customer satisfaction, Tianjin Zhongxin Pharmaceutical Group Corp Ltd ensures the delivery of reliable and trustworthy healthcare solutions.

In which countries and regions is Tianjin Pharmaceutical Da Ren Tang Group Corp primarily present?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is primarily present in China.

What significant milestones has the company Tianjin Pharmaceutical Da Ren Tang Group Corp achieved?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd has achieved several significant milestones. It has successfully expanded its product portfolio, notably in the areas of cardiovascular, respiratory, and anti-infective medicines. The company has also secured numerous international certifications, including Good Manufacturing Practice (GMP) certification, ensuring the highest quality standards. Tianjin Zhongxin Pharmaceutical Group Corp Ltd has made remarkable strides in research and development as well, with several innovative drugs being registered and commercialized. Furthermore, the company has established a robust global presence by entering into strategic partnerships and expanding its market reach. These achievements consolidate Tianjin Zhongxin Pharmaceutical Group Corp Ltd's position as a leading player in the pharmaceutical industry.

What is the history and background of the company Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd, a leading pharmaceutical company, has a rich history and background. Established in [year], the company has been dedicated to providing high-quality healthcare products and services to global markets. With a focus on research and development, manufacturing, and marketing, Tianjin Zhongxin has emerged as a trusted name in the pharmaceutical industry. Its commitment to innovation, quality, and customer satisfaction has enabled it to expand its presence both domestically and internationally. Being one of the prominent players in the pharmaceutical market, Tianjin Zhongxin Pharmaceutical Group Corp Ltd continuously strives for excellence through its diverse product portfolio and relentless pursuit of breakthrough solutions in healthcare.

Who are the main competitors of Tianjin Pharmaceutical Da Ren Tang Group Corp in the market?

The main competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd in the market include other leading pharmaceutical companies such as Shanghai Pharmaceuticals Holding Co., Ltd., Sinopharm Group Co., Ltd., Fosun Pharma, and Jiangsu Hengrui Medicine Co., Ltd.

In which industries is Tianjin Pharmaceutical Da Ren Tang Group Corp primarily active?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd primarily operates in the pharmaceutical industry.

What is the business model of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd focuses on the development, production, and sales of pharmaceutical products. As one of the leading pharmaceutical companies in China, Tianjin Zhongxin Pharmaceutical Group Corp Ltd aims to provide high-quality and affordable medications to improve the health and well-being of individuals. With a diverse product portfolio ranging from traditional Chinese medicine to modern pharmaceuticals, the company emphasizes research and innovation to meet the growing healthcare needs of its customers. By adhering to strict quality standards and maintaining a strong distribution network, Tianjin Zhongxin Pharmaceutical Group Corp Ltd ensures the availability and accessibility of its products nationwide.

Hvilken P/E har Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

Det Tianjin Pharmaceutical Da Ren Tang Group Corp P/E-forhold er 19,99.

Hvad er KUV for Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

Tianjin Pharmaceutical Da Ren Tang Group Corp KUV er 2,65.

Hvilken AlleAktien kvalitetsscore har Tianjin Pharmaceutical Da Ren Tang Group Corp?

AlleAktien Kvalitetsscore for Tianjin Pharmaceutical Da Ren Tang Group Corp er 7/10.

Hvor høj er omsætningen for Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

Den forventede Tianjin Pharmaceutical Da Ren Tang Group Corp omsætning er 9,12 mia. CNY.

Hvor høj er overskuddet for Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

Den forventede Tianjin Pharmaceutical Da Ren Tang Group Corp indtjening er 1,21 mia. CNY.

Hvad laver Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is a Chinese company specialized in the production and sale of pharmaceutical products, health and dietary supplements, and medical devices. Its business model is based on a comprehensive range of products and services that allow it to meet the needs of customers in different markets. The company is divided into several divisions, including the pharmaceutical products division, the dietary supplements division, and the medical devices division. Each of these divisions offers unique products and services tailored to specific needs and requirements. In the field of pharmaceutical products, Tianjin Zhongxin Pharmaceutical Group Corp Ltd manufactures a variety of drugs used to treat various diseases and conditions. This includes antibiotics, anti-inflammatory drugs, cancer medications, as well as treatments for cardiovascular diseases and diabetes. The company also has a research and development department that continuously works on the development of new drugs. The dietary supplements division offers a wide range of products aimed at improving health and well-being. These include vitamins, minerals, enzymes, and herbal extracts. The company adheres to strict standards in the production of its products and uses only high-quality and natural ingredients. The medical devices division of Tianjin Zhongxin Pharmaceutical Group Corp Ltd specializes in the production of medical devices such as blood glucose monitors and blood pressure monitors. These devices are of high quality and comply with all applicable standards and regulations. The business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd also includes collaborations with other companies and organizations around the world. The company has partnerships with a variety of domestic and international companies to expand its product range and strengthen its global presence. Overall, the business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd is focused on the development, production, and sale of high-quality pharmaceutical products, dietary supplements, and medical devices. Its divisions offer a wide range of products and services tailored to the needs of customers in different markets. Through its global presence and collaborations with other companies and organizations worldwide, the company ensures continuous expansion and future success.

Hvor høj er Tianjin Pharmaceutical Da Ren Tang Group Corp udbyttet?

Tianjin Pharmaceutical Da Ren Tang Group Corp udbetaler et udbytte på 0,50 CNY fordelt over udbetalinger om året.

Hvor ofte betaler Tianjin Pharmaceutical Da Ren Tang Group Corp udbytte?

Udbyttet kan for nuværende ikke beregnes for Tianjin Pharmaceutical Da Ren Tang Group Corp, eller selskabet udbetaler ikke udbytte.

Hvad er Tianjin Pharmaceutical Da Ren Tang Group Corp ISIN?

ISIN'en for Tianjin Pharmaceutical Da Ren Tang Group Corp er CNE000001808.

Hvad er Tianjin Pharmaceutical Da Ren Tang Group Corp tickeren?

Tickeren for Tianjin Pharmaceutical Da Ren Tang Group Corp er 600329.SS.

Hvor meget i udbytte betaler Tianjin Pharmaceutical Da Ren Tang Group Corp?

I løbet af de sidste 12 måneder betalte Tianjin Pharmaceutical Da Ren Tang Group Corp en dividende på 1,12 CNY . Dette svarer til et dividendeudbytte på omkring 3,57 %. For de kommende 12 måneder vil Tianjin Pharmaceutical Da Ren Tang Group Corp sandsynligvis betale en dividende på 1,21 CNY.

Hvor høj er udbytteafkastet for Tianjin Pharmaceutical Da Ren Tang Group Corp?

Udbytteafkastet for Tianjin Pharmaceutical Da Ren Tang Group Corp er i øjeblikket 3,57 %.

Hvornår udbetaler Tianjin Pharmaceutical Da Ren Tang Group Corp udbytte?

Tianjin Pharmaceutical Da Ren Tang Group Corp betaler kvartalsvis udbytte. Dette uddeles i månederne juli, juli, juli, juli.

Hvor sikker er udbyttet fra Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Pharmaceutical Da Ren Tang Group Corp betalte udbytte hvert år i løbet af de sidste 16 år.

Hvor høj er udbyttet fra Tianjin Pharmaceutical Da Ren Tang Group Corp?

For de kommende 12 måneder forventes der dividender på 1,21 CNY. Dette svarer til et dividendeafkast på 3,85 %.

I hvilken sektor befinder Tianjin Pharmaceutical Da Ren Tang Group Corp sig?

Tianjin Pharmaceutical Da Ren Tang Group Corp bliver tildelt sektoren 'Sundhed'.

Wann musste ich die Aktien von Tianjin Pharmaceutical Da Ren Tang Group Corp kaufen, um die vorherige Dividende zu erhalten?

For at modtage det seneste udbytte på Tianjin Pharmaceutical Da Ren Tang Group Corp fra den 6.6.2023 på 1,12 CNY, skulle du have haft aktien i din portefølje før ex-datoen den 6.6.2023.

Hvornår betalte Tianjin Pharmaceutical Da Ren Tang Group Corp den seneste udbytte?

Udbetalingen af det sidste udbytte blev foretaget den 6.6.2023.

Hvor høj var udbyttet fra Tianjin Pharmaceutical Da Ren Tang Group Corp i år 2023?

I løbet af 2023 udbetalte Tianjin Pharmaceutical Da Ren Tang Group Corp 0,5 CNY i form af dividender.

I hvilken valuta udbetaler Tianjin Pharmaceutical Da Ren Tang Group Corp udbyttet?

Udbytterne fra Tianjin Pharmaceutical Da Ren Tang Group Corp udbetales i CNY.

1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	769,00	861,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	123,00	114,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,00	-56,00
-84,00	-198,00	-353,00	-350,00	-462,00	-536,00	-667,00	-682,00	-493,00	-471,00	-629,00	-611,00	-737,00	-884,00	-1.370,00	-1.547,00	-1.679,00	-1.664,00	-1.816,00	-2.084,00	-2.305,00	-2.068,00	-2.316,00	-2.255,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-186,00	-191,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-59,00	-93,00	-146,00	-162,00	-180,00	-203,00	-178,00	-198,00	-197,00	-260,00	-254,00	-328,00	-374,00	-424,00	-495,00	-511,00	-505,00	-487,00	-514,00	-554,00	-598,00	-523,00	-496,00	-526,00
69,00	-14,00	157,00	187,00	76,00	10,00	261,00	-28,00	20,00	113,00	83,00	139,00	173,00	20,00	213,00	286,00	360,00	417,00	-4,00	350,00	495,00	671,00	852,00	677,00
-54,00	-79,00	-134,00	-180,00	-589,00	-252,00	-149,00	-63,00	-53,00	-38,00	-86,00	-68,00	-43,00	-41,00	-72,00	-70,00	-92,00	-118,00	-114,00	-175,00	-205,00	-189,00	-156,00	-107,00
74,00	22,00	-67,00	-114,00	-654,00	-109,00	-61,00	120,00	253,00	97,00	22,00	11,00	33,00	22,00	-166,00	102,00	-428,00	86,00	197,00	382,00	-100,00	73,00	-311,00	-12,00
128,00	101,00	66,00	65,00	-65,00	143,00	88,00	184,00	307,00	135,00	108,00	80,00	76,00	63,00	-93,00	172,00	-335,00	204,00	311,00	557,00	104,00	262,00	-154,00	95,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-22,00	-1,00	-244,00	51,00	564,00	114,00	64,00	-51,00	-145,00	-162,00	-49,00	-80,00	5,00	63,00	185,00	-273,00	-367,00	-19,00	-42,00	-10,00	-222,00	0	0	179,00
14,00	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-83,00	-85,00	54,00	-22,00	505,00	-4,00	-67,00	-187,00	-234,00	-246,00	-86,00	-120,00	-197,00	-75,00	266,00	-491,00	273,00	-339,00	-161,00	-252,00	-370,00	-237,00	-244,00	-236,00
-75,00	-83,00	369,00	22,00	28,00	9,00	5,00	0	0	0	19,00	4,00	1,00	0	239,00	-99,00	784,00	-114,00	8,00	-77,00	25,00	-4,00	-12,00	-29,00
0	0	-69,00	-96,00	-87,00	-128,00	-136,00	-136,00	-89,00	-84,00	-56,00	-45,00	-204,00	-138,00	-157,00	-118,00	-143,00	-205,00	-127,00	-164,00	-173,00	-232,00	-232,00	-387,00
0,27	0,20	0,80	0,75	0,65	0,65	1,24	0,76	0,75	0,81	0,99	1,11	1,30	1,30	2,39	2,24	2,75	2,73	2,36	3,47	3,42	3,77	3,96	3,89
14,80	-93,90	23,70	7,20	-512,60	-241,80	112,10	-91,80	-33,60	75,40	-3,30	70,20	130,90	-20,40	141,00	216,70	268,00	299,60	-118,40	174,30	289,90	482,20	695,45	569,34
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Direkte emissioner	—
Indirekte emissioner fra indkøbt energi	—
Indirekte emissioner inden for værdikæden	—
CO₂-emissioner	—
CO₂-reduktionsstrategi	✅
Kulenergi	❌
Atomkraft	❌
Dyreforsøg	✅
Pels & Læder	—
Pesticider	—
Palm-Olie	—
Tobak	❌
Bioteknologi	❌
Klimakoncept	—
Bæredygtigt skovbrug	—
Genanvendelsesregler	❌
Miljøvenlig emballage	❌
Farlige stoffer	❌
Brændstofforbrug og -effektivitet	❌
Vandforbrug og -effektivitet	✅

Kvindelige ansattes andel	—
Kvindelig andel i ledelsen	—
Andel af asiatiske ansatte	—
Andel af asiatisk ledelse	—
Andel af hispano/latino-ansatte	—
Andel af hispano/latino-ledelse	—
Andel af sorte ansatte	—
Andel af sort ledelse	—
Andel af hvide ansatte	—
Andel af hvid ledelse	—
Voksenindhold	❌
Alkohol	❌
Våbenindustri	—
Skydevåben	❌
Hasardspil	❌
Militærkontrakter	❌
Menneskerettighedskoncept	❌
Databeskyttelseskoncept	—
Arbejds- og sundhedsbeskyttelse	✅
Katolsk	✅

Bæredygtighedsrapport	✅
Stakeholder-engagement	❌
Tilbagekaldelsespolitik	❌
Konkurrenceret	❌

Tianjin Pharmaceutical Da Ren Tang Group Corp Ticker	Tianjin Pharmaceutical Da Ren Tang Group Corp FIGI
600329:CH	BBG000CWRRB4
600329:CG	BBG000CWRRX0
600329:C1	BBG00709HMS7

1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0,29	0,41	0,82	1,52	1,84	2,06	2,12	2,52	2,16	2,26	2,37	2,88	3,47	4,39	5,13	6,01	7,09	7,08	6,24	5,69	6,36	6,99	6,60	6,91	8,25	8,22	9,12	10,00	10,96
-	44,06	99,51	85,04	20,91	12,23	2,47	19,01	-14,02	4,34	4,74	21,78	20,59	26,43	16,81	17,18	17,90	-0,08	-11,84	-8,86	11,76	9,99	-5,58	4,60	19,43	-0,33	10,92	9,66	9,58
49,65	50,49	42,58	37,48	36,81	41,72	45,11	42,55	34,98	34,28	36,91	37,53	37,75	34,84	34,12	31,85	30,27	29,48	32,27	38,67	41,19	41,76	39,07	39,76	39,48	43,66	-	-	-
0,14	0,21	0,35	0,57	0,68	0,86	0,95	1,07	0,76	0,77	0,87	1,08	1,31	1,53	1,75	1,91	2,15	2,09	2,01	2,20	2,62	2,92	2,58	2,75	3,26	3,59	0	0	0
0,03	0,04	0,04	0,06	0,06	0,07	0,07	0,05	-0,41	-0,19	0,09	0,17	0,24	0,27	0,27	0,34	0,37	0,39	0,30	0,35	0,47	0,54	0,59	0,59	0,68	0,81	1,08	1,34	1,65
11,19	9,71	4,50	3,81	3,15	3,54	3,45	2,03	-18,85	-8,19	3,89	5,83	6,80	6,17	5,23	5,72	5,25	5,55	4,73	6,12	7,36	7,66	8,89	8,57	8,26	9,90	11,84	13,36	15,09
0,15	0,11	0,09	0,06	0,09	0,09	0,06	0,08	-0,39	-0,07	0,18	0,26	0,29	0,25	0,44	0,35	0,36	0,45	0,42	0,48	0,56	0,63	0,66	0,77	0,86	0,99	1,21	1,46	1,73
-	-22,45	-24,56	-26,74	34,92	1,18	-25,58	25,00	-582,50	-81,87	-351,43	46,02	14,01	-15,70	78,54	-20,41	1,71	26,33	-6,21	12,53	17,86	11,41	5,76	16,34	11,96	14,52	22,41	20,80	18,72
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
659,30	659,30	659,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	768,90	768,90	768,90	769,40	768,90	768,90	769,14	776,39	768,87	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Gør de bedste investeringer i dit liv.

Aktiekurs

Aktiekurs

Ticker600329.SS

ISINCNE000001808

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktiens omsætning, EBIT, indtjening CNE000001808 ·

Omsætning, Overskud & EBIT

Forståelse af Omsætning, EBIT og Indkomst

Årlig Analyse og Sammenligninger

Udnytte Forventninger til Investeringen

Investmentindsigter

Tianjin Pharmaceutical Da Ren Tang Group Corp Omsætning, overskud og EBIT-historik

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktieparametre

GuV

Omsætning og vækst

Bruttomargin

EBIT og EBIT-margin

Indkomst og vækst

Udestående aktier

Fortolkning af årlig sammenligning

Forventninger og prognoser

Balance

Forståelse af balancen

Aktiver

Forpligtelser

Egenkapital

År-efter-år-analyse

Fortolkning af data

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktie Margener CNE000001808 ·

Margen

Forståelse af bruttomargin

Analyse af EBIT-margin

Indsigt i omsætningsmargin

Fortolkning af forventninger

Sammenlignende analyse

Tianjin Pharmaceutical Da Ren Tang Group Corp Margenhistorie

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktie Omsætning, EBIT, Indtjening per aktie CNE000001808 ·

Omsætning, EBIT og indtjening per aktie

Omsætning per aktie

EBIT per aktie

Indkomst per aktie

Forventede værdier

Tianjin Pharmaceutical Da Ren Tang Group Corp Omsætning, overskud og EBIT pr. aktie historik

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktie og aktieanalyse

Tianjin Pharmaceutical Da Ren Tang Group Corp Vurdering ud fra historisk P/E, EBIT og P/S

Tianjin Pharmaceutical Da Ren Tang Group Corp Antal Aktier CNE000001808 ·

Omsætning, EBIT og indtjening per aktie

Omsætning per aktie

EBIT per aktie

Indkomst per aktie

Forventede værdier

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktiesplitninger

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktieudbytte CNE000001808 ·

Dividende

Oversigt over udbytter

Fortolkning og anvendelse

Investeringstrategi

Tianjin Pharmaceutical Da Ren Tang Group Corp Udbyttehistorik

Tianjin Pharmaceutical Da Ren Tang Group Corp Akties udbetalingsrate CNE000001808 ·

Udbetalingsratio

Hvad er den årlige udbetalingsratio?

Sådan tolker du dataene

Brug af data til investeringer

Tianjin Pharmaceutical Da Ren Tang Group Corp Udbetalingskvoteshistorik

Tianjin Pharmaceutical Da Ren Tang Group Corp Indtjeningsforventninger

Tianjin Pharmaceutical Da Ren Tang Group Corp Indtjenings overraskelser

Eulerpool ESG Rating for Tianjin Pharmaceutical Da Ren Tang Group Corp-aktien

Eulerpool World ESG Rating (EESG©)

47/ 100

🌱 Environment

👫 Social

🏛️ Governance

Miljø (Environment)

Sociale (Social)

Virksomhedsledelse (Governance)

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktiens aktionærstruktur

Tianjin Pharmaceutical Da Ren Tang Group Corp Forsyningskæde

Hyppige spørgsmål om Tianjin Pharmaceutical Da Ren Tang Group Corp-aktien

What values and corporate philosophy does Tianjin Pharmaceutical Da Ren Tang Group Corp represent?

In which countries and regions is Tianjin Pharmaceutical Da Ren Tang Group Corp primarily present?

Ticker
600329.SS

ISIN
CNE000001808